Continuing the Conversation: CAR T-Cell Therapy Insights

Continuing the Conversation: CAR T-Cell Therapy Insights is organized by Pharmacy Times Continuing Education (PTCE).,,Release date: July 29, 2022,Expiration date: August 15, 2023,,Description:,The use of chimeric antigen receptor (CAR) T-cell therapies are impacting the treatment of many malignancies, including multiple myeloma and diffuse large B-cell lymphoma. The use of these therapies requires all members of the health care team; there are many factors to consider when selecting therapy, as well as monitoring post-administration due to the potential for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Additionally, care coordination is important, as these therapies often involve teammates in both the inpatient and outpatient healthcare settings.,,Educational Objectives,At the completion of this activity, participants will be able to:,• Characterize known challenges with the development of chimeric antigen receptor T-cell therapy programs,• Distinguish the role of the pharmacist in caring for patients receiving chimeric antigen receptor T-cell therapy